Drugs / Fluzone Quadrivalent High-Dose
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05518500 | Aug 2022 → Dec 2026 expected | premature aging syndrome | The Jackson Laboratory | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone Quadrivalent High-Dose | “Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.” NCT05518500 ↗ |